Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Roxadustat: More Than an Erythropoietic Agent?
Kidney Int Rep
January 2025
Translational Transplant Research Center and Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, USA.
Real-world assessment of the patient profile, clinical characteristics, treatment patterns, and outcomes associated with erythropoietic and X-linked protoporphyria.
J Dermatol
January 2025
Mitsubishi Tanabe Pharma America, Inc., Jersey City, New Jersey, USA.
Article Synopsis
- Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are rare genetic disorders that lack comprehensive management data, prompting a study of their characteristics and treatment in real-world U.S. settings.
- The study reviewed medical records of 299 EPP and 91 XLP patients, revealing a mean diagnosis delay of 2.9 years and highlighting common pre-diagnostic tests and lifestyle recommendations.
- Findings indicated a significant number of healthcare visits post-diagnosis and identified unmet needs, such as the need for quicker diagnoses, effective symptom relief, and better prevention of phototoxic reactions.
Erythropoietin and glial cells in central and peripheral nervous systems.
Mol Biol Rep
October 2024
Department of Physiology and Pharmacology, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Article Synopsis
- Erythropoietin (EPO) is primarily used to treat anemia and also acts as a neuroprotective agent in the central nervous system by binding to its receptor, EPOR, on neurons and glial cells.
- The EPO-EPOR complex initiates specific signaling pathways in glial cells that may influence various neurological disorders, including Alzheimer's, Parkinson's, and conditions like stroke and trauma.
- The review emphasizes EPO's role across different glial cell types and suggests that understanding its non-blood-related actions could improve treatments for CNS disorders and highlight its neuroprotective capabilities.
Inactive Parp2 causes Tp53-dependent lethal anemia by blocking replication-associated nick ligation in erythroblasts.
Mol Cell
October 2024
Institute for Cancer Genetics, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA; Department of Pathology & Cell Biology, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA; Department of Pediatrics, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA; Department of Immunology & Microbiology, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA. Electronic address:
Article Synopsis
- PARP inhibitors (PARPi) show promise in cancer treatment but have been linked to severe anemia and leukemia, complicating their use.
- Research indicates that mice with inactive PARP2 face severe blood production issues, suggesting a critical role of PARP2 in erythropoiesis (red blood cell formation) during development.
- Active PARP2 is essential for DNA replication and repair, particularly at specific DNA damage sites; its inactivity leads to harmful effects in blood cell production, providing insights into the anemia seen with PARPi treatment.
Supplemental Iron and Recombinant Erythropoietin for Anemia in Infants Born Very Preterm: A Survey of Clinical Practice in Europe.
J Pediatr
January 2025
Department of Neonatology, Charité - Universitätsmedizin Berlin, Berlin, Germany. Electronic address:
Objectives: To survey practices of iron and recombinant human erythropoietin (rhEpo) administration to infants born preterm across Europe.
Study Design: Over a 3-month period, we conducted an online survey in 597 neonatal intensive care units (NICUs) of 18 European countries treating infants born with a gestational age of <32 weeks.
Results: We included 343 NICUs (response rate 56.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!